MedTrace Logo

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

NCT03771638 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-03

Study results available
· View outcomes & findings →

Summary

The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill was swallowed. The goal of this study is to assess the impact of the app on adherence to HIV pre-exposure prophylaxis (PrEP) for the prevention of HIV.

Conditions

  • Adherence, Medication
  • Risk Behavior
  • Pre-Exposure Prophylaxis
  • HIV Prevention

Interventions

DRUG

Emtricitabine / Tenofovir Disoproxil Oral Tablet

Open label daily emtricitabine/tenofovir disoproxil oral tablet

OTHER

DOT Diary mobile app

DOT Diary mobile application for tracking medication adherence and sexual activities.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • San Francisco Department of Public Health

    collaborator OTHER_GOV

  • Emory University

    collaborator OTHER

  • AiCure

    collaborator INDUSTRY

  • Public Health Foundation Enterprises, Inc.

    lead OTHER

Principal Investigators

  • Susan Buchbinder, MD · Bridge HIV, San Francisco Department of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-04-21
Completion
2020-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03771638 on ClinicalTrials.gov